| Literature DB >> 34928202 |
Maisem Laabei1, Sharon J Peacock2, Beth Blane2, Sarah L Baines3, Benjamin P Howden3,4, Timothy P Stinear3, Ruth C Massey5.
Abstract
Staphylococcus aureus is a major human pathogen where the emergence of antibiotic resistant lineages, such as methicillin-resistant S. aureus (MRSA), is a major health concern. While some MRSA lineages are restricted to the healthcare setting, the epidemiology of MRSA is changing globally, with the rise of specific lineages causing disease in healthy people in the community. In the past two decades, community-associated MRSA (CA-MRSA) has emerged as a clinically important and virulent pathogen associated with serious skin and soft-tissue infections (SSTI). These infections are primarily cytotoxin driven, leading to the suggestion that hypervirulent lineages/multi-locus sequence types (STs) exist. To examine this, we compared the cytotoxicity of 475 MRSA isolates representing five major MRSA STs (ST22, ST93, ST8, ST239 and ST36) by employing a monocyte-macrophage THP-1 cell line as a surrogate for measuring gross cytotoxicity. We demonstrate that while certain MRSA STs contain highly toxic isolates, there is such variability within lineages to suggest that this aspect of virulence should not be inferred from the genotype of any given isolate. Furthermore, by interrogating the accessory gene regulator (Agr) sequences in this collection we identified several Agr mutations that were associated with reduced cytotoxicity. Interestingly, the majority of isolates that were attenuated in cytotoxin production contained no mutations in the agr locus, indicating a role of other undefined genes in S. aureus toxin regulation.Entities:
Keywords: Staphylococcus aureus; bacterial pathogenesis; bacterial virulence; cytotoxicity
Mesh:
Substances:
Year: 2021 PMID: 34928202 PMCID: PMC8744995 DOI: 10.1099/mic.0.001119
Source DB: PubMed Journal: Microbiology (Reading) ISSN: 1350-0872 Impact factor: 2.777
Fig. 1.Variation in cytotoxicity between and within MRSA sequence types. The cytotoxicity of each isolate from five MRSA STs (ST22 (n=110), ST93 (n=58), ST8 (n=134), ST239 (n=87) and ST36 (n=86)) was quantified by incubating cell-free supernatant (either diluted to 30 % using sterile TS broth or used undiluted (100%)) with cultured THP-1 cells and cytotoxicity examined by flow cytometry. The cytotoxicity of each isolate was quantified using three biological repeats with a single dot representing the mean value for each isolate and the median of each sequence type indicated by the horizontal bars.
Fig. 2.Cytotoxicity of the least and highest toxic isolates from each of the five MRSA sequence type. The supernatant of the five least (a) and highest (b) toxic isolates from each sequence type was diluted to 10, 30, or 70 % supernatant in sterile TS broth or used undiluted (100%) and the percentage cell death of THP-1 cells examined. The cytotoxicity of each isolate was quantified using three biological repeats and the data is presented as the mean and standard deviation across the five isolates.
Fig. 3.Accessory gene regulatory (Agr) system of labelled with amino acid substitutions associated with reduced cytotoxicity. (a) The Agr locus consists of two divergent transcripts driven by the P2 and P3 promoters. P2 drives the expression of the quorum sensing systems consisting of the signal synthesis (agrBD) and signal detection (agrAC) genes. AgrB and AgrD cooperative to process and secrete autoinducing peptides (AIPs) which are sensed by the polytopic transmembrane protein, AgrC. AgrCA function as a two-component signal transduction system with AgrC phosphorylating AgrA resulting in a conformational change promoting DNA binding to the intergenic region between P2 and P3 driving their expression. The effector molecule of the Agr system, RNAIII, is expressed from P3 resulting in a shift in virulence gene expression, namely enhanced cytolytic toxin expression. (b) The C-terminal DNA binding domain of AgrA is shown as a ten-stranded elongated β-β-β sandwich, where the β-strands are shown in blue, helices shown in orange and loop regions shown in grey. Mutation associated with reduced toxicity are highlighted in the specific regions of the protein in which they occur. (c) The transmembrane sensor and cytoplasmic histidine kinase domains of AgrC are highlighted. The central histidine residue (H239) within the H-box of the DHp subdomain and the CA subdomain N-box asparagine (N339) and glycine residues of the G box (G394 and G396) are indicated. Residues labelled in red have been identified in this study to be associated with reduced cytotoxicity.
Comparison of mutations and amino acid substitutions (AA-sub) identified in the accessory gene regulator A (agrA) gene and cytotoxicity of MRSA isolates
|
ST/Strain ID |
Mutation / AA-sub |
Description |
Cell death (%) |
|---|---|---|---|
|
|
|
|
|
|
ASARM205 |
Y95H |
Unknown |
45 |
|
ASARM93 |
E163G |
Glutamic residue lies within beta-sheet 3, important in beta-beta-beta sandwich formation, involved in salt bridge formation |
9 |
|
ASARM207 |
K223Stop |
Dysfunctional, truncated AgrA |
5 |
|
ASARM128 |
K236Stop |
Dysfunctional, truncated AgrA |
3 |
|
| |||
|
Sa_TPS3105 |
Frameshift I156, T178 |
Dysfunctional, truncated AgrA |
6 |
|
| |||
|
MR026 |
(-t)2 149 463 |
Dysfunctional, frameshift and predicted premature stop codon at 173 |
12 |
|
| |||
|
AGT9 |
A47D |
Unknown |
6 |
|
MAL119 |
S139I |
Functional |
91 |
|
| |||
|
EOE120 |
D157Y |
Important in formation of elongated beta-beta-beta fold and salt bridge formation |
4 |
|
ASARM63 |
H169Y |
Dysfunctional, His residue is essential for DNA binding |
5 |
|
EOE176 |
Q179Stop codon |
Dysfunctional, truncated AgrA |
5 |
|
EOE161 |
Q179Stop codon |
Dysfunctional, truncated AgrA |
5 |
|
EOE171 |
Q179Stop codon |
Dysfunctional, truncated AgrA |
5 |
|
EOE169 |
Q179Stop codon |
Dysfunctional, truncated AgrA |
6 |
Comparison of mutations and amino acid substitutions (AA-sub) identified in the accessory gene regulator C (agrC) gene and cytotoxicity of MRSA isolates
|
ST/Strain ID |
Mutation / AA-sub |
Description |
Cell death (%) |
|---|---|---|---|
|
|
| ||
|
ASARM204 |
S47T and V367I |
Mutation in extracellular loop; mutation in cytoplasmic c-terminal domain |
5 |
|
ASARM84 |
M53I |
Unknown; mutation in membrane spanning region |
5 |
|
ASARM224 |
A57V |
Functional |
91 |
|
ASARM217 |
A57V |
Functional |
92 |
|
ASARM208 |
A57V |
Functional |
97 |
|
ASARM61 |
A57V |
Functional |
97 |
|
ASARM200 |
Y121H and Q202H |
Functional |
92 |
|
ASARM201 |
Y121H and Q202H |
Functional |
93 |
|
ASARM154 |
F162V |
Unknown; mutation in membrane spanning region |
13 |
|
ASARM97 |
A340V |
Mutation of highly conserved residue in N-box CA kinase subdomain |
14 |
|
| |||
|
Sa_TPS3155 |
Y71H |
Unknown; mutation in membrane spanning region |
42 |
|
Sa_TPS3165 |
F162S |
Unknown; mutation in membrane spanning region |
15 |
|
Sa_TPS3167 |
M20I |
Unknown; mutation in membrane spanning region |
56 |
|
Sa_TPS3148 |
R235C |
Mutation of conserved residue in H-box in DHp subdomain |
6 |
|
Sa_TPS3151 |
D240N |
Mutation of conserved residue in H-box in DHp subdomain |
12 |
|
Sa_TPS3161 |
G284D |
Mutation in histidine kinase domain -predicted to be dysfunctional |
9 |
|
| |||
|
MR030 |
(-t)2 146 811 |
Deletion (-t;2146811) within intergenic region between P2/P3 agr promoter |
64 |
|
MR081 |
(-t)2 146 811 |
Deletion (-t;2146811) within intergenic region between P2/P3 agr promoter |
23 |
|
MR083 |
(-t)2 146 811 |
Deletion (-t;2146811) within intergenic region between P2/P3 agr promoter |
65 |
|
USFL093 |
Y32T |
Functional |
95 |
|
MR065 |
L381F |
Mutation of non-conserved residue in G-box CA kinase subdomain |
35 |
|
| |||
|
GRE4 |
T246M |
Mutation of conserved residue in H-box in DHp subdomain |
5 |
|
ICP5062 |
T247I |
Mutation of conserved residue in H-box in DHp subdomain |
6 |
|
HU5 |
I311T; A343T |
Dysfunctional; I311T/A343T resulted in delayed RNAIII activity |
15 |
|
HU11 |
I311T; A343T |
Dysfunctional; I311T/A343T resulted in delayed RNAIII activity |
18 |
|
DEU29 |
I311T; A343T |
Dysfunctional; I311T/A343T resulted in delayed RNAIII activity |
19 |
|
DEU37 |
I311T; A343T |
Dysfunctional; I311T/A343T resulted in delayed RNAIII activity |
19 |
|
HU6 |
I311T; A343T |
Dysfunctional; I311T/A343T resulted in delayed RNAIII activity |
120 |
|
DEU20 |
I311T; A343T |
Dysfunctional; I311T/A343T resulted in delayed RNAIII activity |
21 |
|
DEU9 |
I311T; A343T |
Dysfunctional; I311T/A343T resulted in delayed RNAIII activity |
20 |
|
DEU17 |
I311T; A343T |
Dysfunctional; I311T/A343T resulted in delayed RNAIII activity |
16 |
|
HU16 |
I311T; A343T |
Dysfunctional; I311T/A343T resulted in delayed RNAIII activity |
18 |
|
CHI61 |
M326T |
Functional |
80 |
|
| |||
|
EOE173 |
T247I |
Mutation of conserved residue in H-box in DHp subdomain |
6 |
|
EOE096 |
T388I |
Mutation of conserved residue in G-box CA subdomain |
7 |